Literature DB >> 29117613

Evaluation of the Relation Between Omentin-1 and Vitamin D in Postmenopausal Women With or Without Osteoporosis.

Okan Dikker1,2, Seldag Bekpinar1, Gul Ozdemirler3, Mujdat Uysal1, Muberra Vardar2, Sevgi Atar4, Murat Usta5, Berrin Huner4.   

Abstract

INTRODUCTION: Crosstalk between bone and adipose tissues is implicated in several pathologic conditions related to bone metabolism. Omentin-1, a 34-kD protein, is released from omental adipose tissue. A few studies indicated the effect of omentin-1 on bone health and bone mineral density (BMD) and the interaction of omentin-1 with vitamin D. Therefore, this study aimed to investigate the relationship between omentin-1, vitamin D, and BMD in postmenopausal women with osteoporosis compared with non-osteoporotic counterparts.
MATERIALS AND METHODS: Forty postmenopausal women with osteoporosis (OP), 40 counterparts without OP, and 30 premenopausal women were enrolled. Dual-energy X-ray Absorptiometry results, body mass index, and some demographic and biochemical data were recorded. Vitamin D (25-hydroxyvitamin D3) levels were measured using liquid chromatography-tandem mass spectrometry. Serum omentin-1 was determined using an enzyme-linked immunosorbent assay.
RESULTS: Omentin-1 levels tended to increase in both postmenopausal women groups compared with the control group, but this increase was significant only in women with osteoporosis. Vitamin D levels were not different between the groups. When women were categorized according to vitamin D levels, women with normal vitamin D levels had significantly higher omentin-1 levels. A positive correlation was found between omentin-1 and vitamin D levels in all groups (r=0.197, p=0.041, n=110).
CONCLUSION: The tendency to an increase in omentin-1 levels in postmenopausal women with osteoporosis may be due to a physiologic compensation against bone loss after menopause. The linear relationship between omentin-1 and vitamin D suggests that adipose tissue is one of the target tissues for the vitamin D effect. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29117613     DOI: 10.1055/s-0043-120110

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

1.  Association of Circulating Omentin-1 with Osteoporosis in a Chinese Type 2 Diabetic Population.

Authors:  Pijun Yan; Yong Xu; Zhihong Zhang; Jianhua Zhu; Ying Miao; Chenlin Gao; Qin Wan
Journal:  Mediators Inflamm       Date:  2020-10-15       Impact factor: 4.711

2.  Effects of Vitamin D Supplementation on Omentin-1 and Spexin Levels, Inflammatory Parameters, Lipid Profile, and Anthropometric Indices in Obese and Overweight Adults with Vitamin D Deficiency under Low-Calorie Diet: A Randomized Placebo Controlled Trial.

Authors:  Elhameh Cheshmazar; Agha Fatemeh Hosseini; Bahareh Yazdani; Elham Razmpoosh; Mitra Zarrati
Journal:  Evid Based Complement Alternat Med       Date:  2020-11-10       Impact factor: 2.629

3.  Changes of circulating neuregulin 4 and its relationship with 25-hydroxy vitamin D and other diabetic vascular complications in patients with diabetic peripheral neuropathy.

Authors:  Pijun Yan; Zhihong Zhang; Ying Miao; Yong Xu; Jianhua Zhu; Qin Wan
Journal:  Diabetol Metab Syndr       Date:  2020-05-19       Impact factor: 3.320

4.  Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females.

Authors:  Saba Tariq; Sundus Tariq; Shahad Abduljalil Abualhamael; Muhammad Shahzad
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

5.  Study on Omentin-1 and miR-502-3p in osteoporotic fracture.

Authors:  Jing Zhang; Yun Hou; Zhaoli Wang; Peng Zhou; Ping Zhang; Jixian Wang; Zhengang Sun; Liyun Wang
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-06-01       Impact factor: 2.041

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.